65,437 trials
Pulmonary Infections · Pseudomonas Aeruginosa in Cystic Fibrosis
Primary: Percentage of Participants With Treatment Emergent Adverse Events, Serious Adverse Events (SAEs) and Deaths — 85.4; 31.2; 0.0 Percentage of participants
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) Antibodies. — 27; 10; 9; 8 subjects
Weight
Primary: Predictive Performance of the Mercy TAPE (Percent of Participants Predicted Within 20% of Their Actual Weight) — 98.1; 93.3 percentage of participants
Dose Finding Study
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 0; 16.7; 0; 16.7 percentage of participants
Migraine
Primary: Mean Headache Days — 0.88; -0.52 headache days/ 28 day period — p=0.30
Pulmonary Disease, Chronic Obstructive
Primary: Time to First Moderate or Severe On-treatment COPD Exacerbation — 107.0; 110.0 days — p=0.3497
Idiopathic Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA) — 82.4…
Rectal Neoplasms
Primary: Rate of T Stage Downstaging — 71 percentage of participants
Renal Insufficiency · Renal Impairment
Primary: Geometric Least Squares Mean Area Under the Plasma Drug Concentration-time Curve From Time Zero to Infinity (AUC0-∞) Following a Single IV Dose of Sugammadex — 339; 151…
HIV Infections
Primary: HIV Viral Load < 400 Copies/ml — 40; 50 percentage of participants
Cardiac Condition
Primary: See Primary Outcome Description Below — 8; 3; 8; 3 participants
Fatigue
Primary: Liver Enzymes — 52.1; 59.1; 81.0; 81.6 U/L
Quality of Life
Primary: Feasibility of Patient Recruitment to Yoga Intervention — 15; 1.5 participants
Retinal Vein Occlusion · Macular Edema
Primary: Time to First Re-treatment — 157 days
Low Back Pain
Primary: Participant Adherence With Education + Exercise Visits — 9; 19 participants